Utilizing Immune Monitoring in Next Generation Immunotherapy Trials
Thomas O. Kleen, Ph.D., Executive Vice President, Immune Monitoring, Epiontis GmbH, Germany
Dr. Thomas Kleen outlines some of the challenges biomarker discovery, discusses his role in the STIC/FDA Immunotherapy Biomarkers Taskforce, and the focus of his work at Epiontis as the Executive Vice President of Immune Monitoring in this podcast for the Biomarkers for Immunotherapy conference at Molecular Diagnostics Europe Summit.